|
|
|
|
|
Alefacept
drug data and news
Alefacept drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Alefacept | ||
| Brand Names/Synonyms | Amevive; Amevive (Biogen Inc.) | ||
| Indication | For treatment of moderate to severe chronic plaque psoriasis | ||
| Sponsored links | Description | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | |
| Pharmacology | Interferes with lymphocyte activation by specifically binding to the lymphocyte antigen, CD2, and inhibiting LFA-3/CD2 interaction. Activation of T lymphocytes involving the interaction between LFA-3 on antigen-presenting cells and CD2 on T lymphocytes plays a role in the pathophysiology of chronic plaque psoriasis. Also causes a reduction in subsets of CD2+ T lymphocytes as well as CD4+ and CD8+ T lymphocytes. | ||
| Mechanism Of Action | Inhibits T-lymphocyte activation and production by binding to the CD2 lymphocyte antigen. | ||
| Alefacept News (When available) |
Alnylam Appoints Dr. Akshay Vaishnaw as Vice President, Clinical ... Feb 7, 2006 Inflammatory Diseases - Both Chronic Diseases, Such as Rheumatoid ... Feb 1, 2006 | ||
| Dosage Forms | POWDER FOR SOLUTION | ||
| Drug_Category | Immunomodulatory Agents; Immunosuppresants; misc. skin and mucous membrane agents (84:92.00) | ||
| Absorption | Not Available | ||
| Interactions | Not Available | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | Human LFA-3/IgG1 fusion protein | ||
| Chemical Formula | C2306H3594N610O694S26 | ||
| Molecular Weight | 51801.1 | ||
| Smiles String | Not Available | ||
| Melting Point | Not Available | ||
| Water Solubility | Not Available | ||
| State | Transparent, slightly viscous, aqueous liquid | ||
| LogP/Hphobicity | -0.432 | ||
| Isoelectric Point | 7.86 | ||
| Biotransformation | Not Available | ||
| Half Life | ~270 hours | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Alefacept.html http://www.rxlist.com/cgi/generic3/amevive.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | BIOD00055 | ||
| CAS Registry Number | 222535-22-0 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | Not Available | ||
| PharmGKB ID | PA10009 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2259052 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |